<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20170130032313N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2018-06-08</date_registration>
      <primary_sponsor>Shahroud University of Medical Sciences</primary_sponsor>
      <public_title>The effect of nitrous oxide inhaled isoferons on postoperative pain "The effect of Remifentanil propofol on postoperative pain</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of inhalational Isoflurane-Nitrous oxide anesthesia and intravenous Propofol-Remifentanil anesthesia on postoperative pain in open reduction and internal fixation of leg and ankle.</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2018-05-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/30909</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: According to randomized quadruple blocks,researcher gives a predetermined series of 60 A and B cards to the anesthetist and based on this pattern participants will assign in to either intervention (A) or control (B) group. After the examination of the patient, After examination of the patient, anesthetist gives information about this study to every participant that has inclusion criteria,, removes an envelope in the order specified (blind concealment) and based on the envelope, group A and B is determined. Researcher and analyst before the end of the study are not aware of the type of intervention in the two groups A and B and  and only the type of the group is recorded in the questionnaire, Blinding description: The patient is unaware of his grouping. The analysis and analysis of the consequences are done by unknown scholars of grouping. The questionnaire consists of two parts, each containing both parts of a single code.
After the anesthetic, the section containing the patient's demographic information is separated and the patient will record the outcome of the postoperative pain in the second part.</study_design>
      <phase>3</phase>
      <hc_freetext>Postoperative pain intensity in candidal patients for open leg and ankle surgery.</hc_freetext>
      <i_freetext>In both groups, the patients are kept at least 8 hours fasting and prescribed by a safe line prior to anesthesia (fentanyl, one microgram per kilogram of weight). Anesthesia starts with Propofol injection of 2mg / kg and muscle relaxation with 0.5 mg / kg atracurium injections. Then, anesthesia is performed in the intervention group: Remifentanil 0.25 μg / kg / min + Propofol 150 μg / kg / min, which is equivalent to 60 ml propofol 1% per hour and 20 ml remifentanil per hour (concentration 50 μg / ml). The patient will be ventilated with 50% oxygen. In the control group, anesthesia with nitrous oxide with oxygen (50% O2 / 50% N2O) and isoflurane (1.5%-1.2%) will continue to be carried out in both groups of cardiovascular and respiratory monitoring And the depth of anesthesia will be adjusted according to the clinical symptoms. Muscle promoter can be repeated in both groups. In recovery, pethidine pain will be given at a dose of 20 mg. After transfer to the unit, if pethidine is present, it will be prescribed 20 mg every 6 hours..</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is All of the writers dont agree with it</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Niloofar Khoobestani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>بلوار مرزداران- خیبان فرشتگان- فرشته ۲-پلاک ۷-زنگ ۱</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>14637-74514</zip>
        <telephone>+98 21 4422 0262</telephone>
        <email>niloofar.kh71@yahoo.com</email>
        <affiliation>Shahroud University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Niloofar Khoobestani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No7.Fereshteh2,Fereshtegan street,Marzdaran Blvdd</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>14637-74514</zip>
        <telephone>+98 21 4422 0262</telephone>
        <email>niloofar.kh71@yahoo.com</email>
        <affiliation>Shahroud University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Male or female
Age between 18 until 40
ASA class 1,2
Patients with open fractures of leg &amp; ankle</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>A history of drug use and drug abuse
Anticonvulsant intake, sedative, anti-depressant
Any complications that change the procedure and anesthesia</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>In both groups, the patients are kept at least 8 hours fasting and prescribed by a safe line prior to anesthesia (fentanyl, one microgram per kilogram of weight). Anesthesia starts with Propofol injection of 2mg / kg and muscle relaxation with 0.5 mg / kg atracurium injections. Then, anesthesia is performed in the intervention group: Remifentanil 0.25 μg / kg / min + Propofol 150 μg / kg / min, which is equivalent to 60 ml propofol 1% per hour and 20 ml remifentanil per hour (concentration 50 μg / ml). The patient will be ventilated with 50% oxygen. In the control group, anesthesia with nitrous oxide with oxygen (50% O2 / 50% N2O) and isoflurane (1.5%-1.2%) will continue to be carried out in both groups of cardiovascular and respiratory monitoring And the depth of anesthesia will be adjusted according to the clinical symptoms. Muscle promoter can be repeated in both groups. In recovery, pethidine pain will be given at a dose of 20 mg. After transfer to the unit, if pethidine is present, it will be prescribed 20 mg every 6 hours.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain score with NRS questionnaire. Timepoint: 2,4,6 hours after transfer of the ward then every 6 hours within 24 hours. Method of measurement: NRS  questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Dose of pethidine prescribed. Timepoint: 2,4,6 hours after transfer to ward then every 6 hours within 24 hours. Method of measurement: NRS questionnaire.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shahroud University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2016-11-09</approval_date>
        <contact_name>Ethics committee of shahrud university of medical sciences</contact_name>
        <contact_address>Shahrud university of medical sience, Haftetir Squard Shahrud Semnan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
